BD 001
Alternative Names: B-D 001Latest Information Update: 23 Sep 2002
Price :
$50 *
At a glance
- Originator Bio-Discovery
- Class
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 23 Sep 2002 Zymogenetics did not exercise its option to license BD 001
- 19 Sep 2002 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
- 27 Nov 2000 ZymoGenetics is now an independent company